P Wheatley-Price1, M Ali2, K Balchin3, J Spencer4, E Fitzgibbon5, C Cripps1. 1. Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON. 2. Postgraduate Medical Education, University of Ottawa, Ottawa, ON. 3. Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON. 4. Division of Pharmacy, The Ottawa Hospital Cancer Centre, Ottawa, ON. 5. Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, ON.
Abstract
BACKGROUND: Hospitalized patients with advanced cancer often have a poor performance status, which is considered a relative contraindication to cytotoxic chemotherapy. We investigated outcomes in hospitalized solid tumour oncology patients who received palliative chemotherapy (pct). METHODS: With ethics approval, we performed a single-institution chart review of all patients hospitalized on our oncology unit who received pct between April 2008 and January 2010. Patient demographics, reasons for admission, cancer type, prior therapy, and administered chemotherapy were recorded. The primary endpoint was median survival from date of inpatient chemotherapy until death or last known follow up. We also investigated place of discharge and whether patients received additional therapy. RESULTS: During the study period, 199 inpatients received pct. Median age was 61 years; 59% of the patients were women. Most had been admitted with dyspnea (31%) or pain (29%) as the dominant symptom. Common cancers represented were breast (23%), small-cell lung cancer (sclc, 22%), non-small-cell lung cancer (nsclc, 16%), and colorectal cancer (9%). Most patients (67%) were receiving first-line chemotherapy. Median overall survival duration was 4.5 months, and the 6-month survival rate was 41%. The longest and shortest survivals were seen in the sclc and nsclc groups (7.3 and 2.5 months respectively). Factors significantly associated with shorter survival were baseline hypoalbuminemia and therapy beyond the first line. In this cohort, 77% of patients were discharged home, and 72% received further chemotherapy. CONCLUSIONS: Despite a short median survival, many patients are well enough to be discharged home and to receive further chemotherapy. The development of risk models to predict a higher chance of efficacy will have practical clinical utility.
BACKGROUND: Hospitalized patients with advanced cancer often have a poor performance status, which is considered a relative contraindication to cytotoxic chemotherapy. We investigated outcomes in hospitalized solid tumour oncologypatients who received palliative chemotherapy (pct). METHODS: With ethics approval, we performed a single-institution chart review of all patients hospitalized on our oncology unit who received pct between April 2008 and January 2010. Patient demographics, reasons for admission, cancer type, prior therapy, and administered chemotherapy were recorded. The primary endpoint was median survival from date of inpatient chemotherapy until death or last known follow up. We also investigated place of discharge and whether patients received additional therapy. RESULTS: During the study period, 199 inpatients received pct. Median age was 61 years; 59% of the patients were women. Most had been admitted with dyspnea (31%) or pain (29%) as the dominant symptom. Common cancers represented were breast (23%), small-cell lung cancer (sclc, 22%), non-small-cell lung cancer (nsclc, 16%), and colorectal cancer (9%). Most patients (67%) were receiving first-line chemotherapy. Median overall survival duration was 4.5 months, and the 6-month survival rate was 41%. The longest and shortest survivals were seen in the sclc and nsclc groups (7.3 and 2.5 months respectively). Factors significantly associated with shorter survival were baseline hypoalbuminemia and therapy beyond the first line. In this cohort, 77% of patients were discharged home, and 72% received further chemotherapy. CONCLUSIONS: Despite a short median survival, many patients are well enough to be discharged home and to receive further chemotherapy. The development of risk models to predict a higher chance of efficacy will have practical clinical utility.
Entities:
Keywords:
Inpatients; hospitalization; palliative chemotherapy; performance status
Authors: T Ohnoshi; S Hiraki; Y Nakata; S Ozawa; T Tamura; T Seto; M Miyai; S Kawahara; T Numata; I Kimura Journal: Acta Med Okayama Date: 1982-12 Impact factor: 0.892
Authors: Alfonso Sánchez-Muñoz; Elisabeth Pérez-Ruiz; María Isabel Sáez; José Manuel Trigo; M Mar Galindo; Lourdes Manzaneque; Begoña Jiménez; Begoña Muros; Emilio Alba Journal: Clin Transl Oncol Date: 2011-06 Impact factor: 3.405
Authors: A Ploquin; D Olmos; D Lacombe; R A'Hern; A Duhamel; C Twelves; S Marsoni; R Morales-Barrera; J-C Soria; J Verweij; E E Voest; P Schöffski; J H Schellens; A Kramar; R S Kristeleit; H-T Arkenau; S B Kaye; N Penel Journal: Br J Cancer Date: 2012-08-21 Impact factor: 7.640
Authors: Adinda Mieras; Bregje D Onwuteaka-Philipsen; Annemarie Becker-Commissaris; Jose C M Bos; H Roeline W Pasman Journal: BMC Palliat Care Date: 2020-06-19 Impact factor: 3.234
Authors: Adinda Mieras; Annemarie Becker-Commissaris; H Roeline W Pasman; Anne-Marie M C Dingemans; Edith V Kok; Robin Cornelissen; Wouter Jacobs; Jan Willem van den Berg; Alle Welling; Brigitte A H A Bogaarts; Lemke Pronk; Bregje D Onwuteaka-Philipsen Journal: Eur J Cancer Care (Engl) Date: 2019-12-21 Impact factor: 2.328